Hedge Funds Continue Dumping Global Blood Therapeutics Inc (GBT)
At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting period.
Global Blood Therapeutics Inc. (GBT)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 4,152,689 | $145,427 | -18% | 1.88% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 3,217,441 | $112,675 | 0.49% | |
| 3. | Point72 Asset Management Steve Cohen | 2,061,600 | $72,197 | +56% | 0.32% |
| 4. | Casdin Capital Eli Casdin | 1,310,000 | $45,876 | +46% | 1.16% |
| 5. | Yiheng Capital Jonathan Guo | 1,275,800 | $44,679 | +35% | 1.79% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.96 | 500 | Officer | 5,161 | 2021-05-10 | Filing | |
| $52.37 | 10,000 | Director | 31,428 | 2020-03-13 | Filing | |
| $38.00 | 175,000 | Large Shareholder | 4,889,066 | 2017-12-19 | Filing | |
| $20.00 | 25,000 | Officer | 25,000 | 2015-08-17 | Filing | |
| $22.36 | 1,000 | Officer | 1,500 | 2016-01-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.21 | 4,800 | Director | 3,037 | 2021-09-09 | Filing | |
| $36.54 | 1,609 | Director | 3,684 | 2021-06-18 | Filing | |
| $36.54 | 1,065 | Director | 6,772 | 2021-06-18 | Filing | |
| $60.00 | 4,532 | Officer | 0 | 2020-10-05 | Filing | |
| $63.77 | 2,200 | Officer | 5,244 | 2020-08-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,000 | $25,480 | 0% | |
| 2. | 179,806 | $4,581 | 0.03% | |
| 3. | 64,051 | $1,632 | 0.58% | |
| 4. | 21,450 | $548 | 0% | |
| 5. | 14,916 | $381 | 0.05% |
News See All
Is GBT Stock A Buy or Sell?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
5 Best Biotech Stocks to Invest In
A clinical-stage biopharmaceutical company Global Blood Therapeutics, Inc. (NASDAQ: GBT) is the long-running investment of a billionaire hedge fund manager.
Hedge Funds Have Never Been This Bullish On Global Blood Therapeutics Inc (GBT)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Did Hedge Funds Make The Right Call On Global Blood Therapeutics Inc (GBT) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Global Blood Therapeutics Inc (GBT): Hedge Funds In Wait-and-See Mode
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Dumping Global Blood Therapeutics Inc (GBT)
We hate to say this but, we told you so.
Hedge Fund Favorites vs. Global Blood Therapeutics Inc (GBT) In 2019
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Did Hedge Funds Drop The Ball On Global Blood Therapeutics Inc (GBT)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Hedge Funds Have Never Been More Bullish On Global Blood Therapeutics Inc (GBT)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Billionaire Hedge Funds
